You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Refractory Hodgkin Lymphoma

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Relapsed or Refractory Hodgkin Lymphoma Trial in Beijing (SHR2554+ SHR1701, SHR-1701)

Recruiting
  • Relapsed or Refractory Hodgkin Lymphoma
  • Beijing, Beijing, China
    Han wei dong
Jun 14, 2023

Hodgkin Lymphoma, Refractory Hodgkin Lymphoma, Relapsed Hodgkin's Disease, Adult Trial in Leon (Brentuximab Vedotin 50 MG

Recruiting
  • Hodgkin Lymphoma
  • +2 more
  • Brentuximab Vedotin 50 MG [Adcetris]
  • Leon, Guanajuato, Mexico
    Hospital Regional Alta Especialidad Bajio
Oct 24, 2022

Hodgkin Lymphoma Trial in Moscow (Nivolumab)

Recruiting
  • Hodgkin Lymphoma
  • Moscow, Russian Federation
    National Research Center for Hematology
Dec 13, 2022

Relapsed Hodgkin Lymphoma, Refractory Hodgkin Lymphoma Trial in Chapel Hill (Nivolumab, Pembrolizumab)

Recruiting
  • Relapsed Hodgkin Lymphoma
  • Refractory Hodgkin Lymphoma
  • Nivolumab
  • Pembrolizumab
  • Chapel Hill, North Carolina
    Lineberger Comprehensive Cancer Center at University of North Ca
Jul 22, 2022

Hodgkin's Lymphoma Trial in Houston (Azacytidine, Pembrolizumab)

Recruiting
  • Hodgkin's Lymphoma
  • Houston, Texas
    MD Anderson Cancer Center
Oct 5, 2022

Relapsed or Refractory Hodgkin Lymphoma, Peripheral T Cell Lymphoma Trial (AFM13, AB-101, Cyclophosphamide)

Not yet recruiting
  • Relapsed or Refractory Hodgkin Lymphoma
  • Peripheral T Cell Lymphoma
  • (no location specified)
May 30, 2023

Hodgkin Lymphoma Trial in New York (Mocetinostat Plus Brentuximab Vedotin)

Completed
Has Results
  • Hodgkin Lymphoma
  • Mocetinostat Plus Brentuximab Vedotin
  • New York, New York
    Memorial Sloan Kettering Cancer Center
May 10, 2022

Hodgkin Lymphoma, Relapsed Hodgkin's Disease, Adult, Refractory Hodgkin Lymphoma Trial in Boston (Nivolumab, Ipilimumab)

Recruiting
  • Hodgkin Lymphoma
  • +2 more
  • Boston, Massachusetts
  • +2 more
Oct 18, 2022

Recurrent Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Refractory Hodgkin Lymphoma Trial in Seattle (drug, other,

Recruiting
  • Recurrent Hodgkin Lymphoma
  • +3 more
  • Brentuximab Vedotin
  • +2 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Oct 4, 2022

Hodgkin Lymphoma Trial (Gemcitabine, Dexamethasone, Cisplatin)

Not yet recruiting
  • Hodgkin Lymphoma
  • (no location specified)
May 9, 2022

Relapsed/Refractory Non-Hodgkin Lymphoma Trial in Duarte, Amsterdam (BMS-986458, Rituximab)

Not yet recruiting
  • Relapsed/Refractory Non-Hodgkin Lymphoma
  • Duarte, California
  • +1 more
Oct 13, 2023

Classical Hodgkin Lymphoma, Non-Hodgkin Lymphoma Trial (GEN3017)

Not yet recruiting
  • Classical Hodgkin Lymphoma
  • Non-Hodgkin Lymphoma
  • GEN3017
  • (no location specified)
Aug 25, 2023

Non-hodgkin's Lymphoma Trial in Beijing (GNC-035)

Not yet recruiting
  • Non-hodgkin's Lymphoma
  • Beijing, Beijing, China
    Beijing Cancer Hospital
Sep 27, 2023

Non-hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma Trial in Boston (CD79b-19 CAR T cells,

Not yet recruiting
  • Non-hodgkin Lymphoma
  • +9 more
  • CD79b-19 CAR T cells
  • +2 more
  • Boston, Massachusetts
    Massachusetts General Hospital
Sep 6, 2023

Relapsed/Refractory Classical Hodgkin Lymphoma Trial in Goyang (Brentuximab vedotin)

Recruiting
  • Relapsed/Refractory Classical Hodgkin Lymphoma
  • Brentuximab vedotin
  • Goyang, Gyeonggi-do, Korea, Republic of
    Hyeon-Seok Eom
Feb 12, 2022

Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma Trial in Duarte (Brentuximab Vedotin, Cyclosporine, Pharmacokinetic

Active, not recruiting
  • Recurrent Hodgkin Lymphoma
  • Refractory Hodgkin Lymphoma
  • Brentuximab Vedotin
  • +4 more
  • Duarte, California
    City of Hope Medical Center
Feb 17, 2022

Non-hodgkin Lymphoma Trial (CD38-SADA:177Lu-DOTA Complex)

Not yet recruiting
  • Non-hodgkin Lymphoma
  • CD38-SADA:177Lu-DOTA Complex
  • (no location specified)
Aug 15, 2023

Relapsed or Refractory B Cell Non-Hodgkin Lymphoma Trial (C-CAR066)

Not yet recruiting
  • Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
  • (no location specified)
Mar 23, 2023

Refractory or Relapsed B-cell Non-Hodgkin Lymphoma Trial in Shanghai (dualCAR-NK19/70 cell)

Recruiting
  • Refractory or Relapsed B-cell Non-Hodgkin Lymphoma
  • dualCAR-NK19/70 cell
  • Shanghai, Shanghai, China
    Shanghai Tongji Hospital, Tongji University School of Medicine
Apr 24, 2023

Non Hodgkin Lymphoma Trial in New York, Clayton, Frankston (IPH6501)

Not yet recruiting
  • Non Hodgkin Lymphoma
  • New York, New York
  • +2 more
Oct 12, 2023

Non-hodgkin Lymphoma Trial (HY004)

Not yet recruiting
  • Non-hodgkin Lymphoma
  • HY004
  • (no location specified)
Aug 21, 2023

Lymphoma, Non-Hodgkin's, Adult Trial (SP-3164)

Not yet recruiting
  • Lymphoma, Non-Hodgkin's, Adult
  • (no location specified)
Aug 4, 2023

Hodgkin's Lymphoma Trial in Milan (histone deacetylase inhibitor (ITF2357))

Terminated
  • Hodgkin's Lymphoma
  • histone deacetylase inhibitor (ITF2357)
  • Milan, Italy
    Istituto Nazionale per lo studio e la cura dei Tumori
Jan 18, 2022

Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Trial in Suzhou (Obinutuzumab, Zanubrutinib, Lenalidomide)

Enrolling by invitation
  • Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
  • Suzhou, Jiangsu, China
    the First Affiliated Hospital of Soochow University
Mar 22, 2023

B-cell Non Hodgkin Lymphoma Trial (Odronextamab, Loncastuximab tesirine, Rituximab)

Not yet recruiting
  • B-cell Non Hodgkin Lymphoma
  • (no location specified)
Aug 7, 2023